Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 2-Part, Phase 1, Multi-Center, Single-Dose, Open Label, Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CSL889 in Adult Patients With Sickle Cell Disease

NCT04285827 is registered in ClinicalTrials.gov with CSL Behring as lead sponsor.

NCT NCT04285827
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04285827 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 2-Part, Phase 1, Multi-Center, Single-Dose, Open Label, Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CSL889 in Adult Patients With Sickle Cell Disease
Lead sponsor
CSL Behring
Phase
Phase 1
Overall status
Completed
Start date
May 20, 2021
Completion date
July 24, 2023
Enrollment
28 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

sickle cell disease